Seattle Children’s Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia … – PR Newswire (press release)
|
Seattle Children’s Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia …
PR Newswire (press release) SEATTLE, July 27, 2017 /PRNewswire-USNewswire/ — After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT-02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving … |
The Scientist |
Stem Cells in the Hypothalamus Slow Aging in Mice
The Scientist Cai and his team found that killing hypothalamic neural stem cells accelerates aging, and transplantation additional neural stem cells into the brain region slows it down. Further, the stem cells‘ anti-aging effects could be reproduced simply by … 5 Ways To Reverse Aging: Science As The Fountain Of YouthInternational Business Times |
Labiotech.eu (blog) |
Swiss Researchers Unveil Cancer Immunotherapy Resistance …
Labiotech.eu (blog) Scientists from the University of Zurich have identified an epigenetic switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. Shedding Light on Cause of Resistance to Tumor ImmunotherapyDrug Discovery & Development |
Xconomy |
Immunotherapy Shakeup: AstraZeneca Inks Merck Deal as Drug Combo Fails
Xconomy AstraZeneca disclosed this morning that a combination of two of its immunotherapy drugs, durvalumab (Imfinzi) and tremelimumab, failed to best chemotherapy at keeping patients’ lung cancers from spreading, one of the main goals of the Mystic trial. Bristol-Myers slides with Wall St eyeing key cancer drugFinancial Times Bristol-Myers shares slump after failed AstraZeneca drug trialReuters Bristol-Myers shares fall after failed AstraZeneca drug trialNasdaq |
|
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in …
Nasdaq “While early, these data highlight the potential for Genethon’s micro-dystrophin gene therapy program and once again underscore the significance of dystrophin production in the treatment of DMD,” said Douglas Ingram, Sarepta’s president and chief … |
Curetoday.com |
Patients’ Gray Hair Turns Dark After Immunotherapy for Lung Cancer
Curetoday.com The study, which was published in JAMA Dermatology, examined 14 patients who have non-small cell lung cancer (NSCLC) and were receiving immunotherapy treatments including one of the following agents: Opdivo (nivolumab), Keytruda (pembrolizumab) … |